Ipsen, Marengo Therapeutics ink oncology partnership
上市批准引进/卖出免疫疗法细胞疗法临床3期
Ipsen and Marengo Therapeutics, have inked a partnership to advance two preclinical candidates from Marengo’s STAR platform into clinical development.
Under the terms of the agreement, Ipsen will make an upfront payment of $45 million to Marengo, with potential milestone payments that could total up to $1.592 billion, plus tiered sales royalties. Marengo will lead preclinical development efforts and cover related costs until the submission of an Investigational New Drug application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization following the IND submission.
Ipsen focuses on developing drugs in oncology, rare diseases, and neuroscience. Marengo Therapeutics, an ATP company, specializes in developing therapeutics that activate specific T cell responses to combat cancer. Marengo’s STAR platform creates selective T cell activators aimed at generating functional, cancer-killing T cells for solid tumors.
Just a few months ago, Ipsen snagged FDA approval for Onivyde (irinotecan liposome) combined with oxaliplatin, fluorouracil, and leucovorin as a first-line treatment for metastatic pancreatic adenocarcinoma, based on the NAPOLI 3 trial. Onivyde, a liposomal topoisomerase inhibitor acquired from Merrimack Pharmaceuticals in 2017, disrupts DNA replication in cancer cells.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。